ClinicalTrials.gg
CompletedNCT01022996Updated May 18, 2016Results posted

Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.

A Phase 2 interventional study of Everolimus (RAD001) in Hodgkin Lymphoma, sponsored by Novartis Pharmaceuticals. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-05-18.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
57
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 970 studies in Hodgkin Disease with a site in United States — 75 open to participants now, 142 under way, 6 of them phase 3. Hodgkin Disease · United States.

Enrollment
256th of 818
57 · median 35
Started
2009
with 45 others
Phase 2
346 of 970
30 open now
Registered
505th of 970
by date

Among the 970 studies in Hodgkin Disease with a site in United States, this one is the 256th largest by enrollment of the 818 interventional ones that give a count, is one of 46 that started in 2009, is one of 346 in phase 2, and was the 505th registered.

Hodgkin Disease

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

75 of the 970 studies in Hodgkin Disease with a site in United States are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 970 studies in Hodgkin Disease with a site in United States, or all of them as a file.
02

Study summary

This study will assess RAD001 in patients with refractory or relapsed Hodgkin Lymphoma that has progressed after high-dose chemotherapy and Autologous Stem cell transplant and/or after gemcitabine- or vinorelbine- or vinblastine-based treatment.

03

Conditions studied

  • Hodgkin Lymphoma

Keywords

  • Hodgkin's Lymphoma
  • Hodgkin Lymphoma
  • Hodgkin's Disease
  • Hodgkin Disease
  • Lymphoma
  • Lymphoproliferative Disorders
  • Neoplasms by Histological type
  • Lymphatic Diseases
  • Hemic and Lymphatic Diseases
  • Recurrent Lymphoma
  • Refractory Lymphoma
  • Relapsed Lymphoma
  • Classical Hodgkin Lymphoma
  • Classical Hodgkin's Disease
  • Nodular sclerosing Hodgkin Lymphoma
  • Mixed-cellularity Hodgkin Lymphoma
  • Lymphocyte-rich Hodgkin Lymphoma
  • Lymphocyte depleted Hodgkin Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a history of classical Hodgkin's lymphoma that has progressed after high-dose chemotherapy and Stem cell transplant and/or after gemcitabine- or vinorelbine- or vinblastine-based treatment
  • Patients with at least one site of measuring ≥ 2.0cm confirmed by PET and CT Scan (or MRI)
  • Patients with adequate bone marrow, liver and renal function (confirmed by laboratory values)
  • Patients with fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fasting triglycerides ≤ 2.5 x

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with mTOR inhibitors
  • Prior stem cell transplant
  • Chemotherapy, monoclonal antibody therapy, major surgery or treatment with other drugs within 4 weeks of starting study treatment
  • Another within 3 years of study entry (except adequately treated non-melanoma skin cancer and carcinoma in situ of the cervix)
  • Severe and/or uncontrolled medical conditions that could affect participation in this study
  • Female patients who are pregnant or breastfeeding; patients who are not willing to use adequate during the study and for 8 weeks after the last study treatment Other protocol-defined inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    RAD001

    Patients with a history of classical Hodgkin lymphoma (ie, nodular sclerosing, mixed cellularity, lymphocyte-rich, lymphocyte-depleted) whose disease had progressed after receiving high-dose chemotherapy with AHSCT (if eligible) and/or after therapy with a gemcitabine- or vinorelbine- or vinblastine-containing regimen, were enrolled into this study. All patients were assigned to a daily dose of everolimus 10 mg (two 5-mg tablets), selfadministered orally and continuously from Cycle 1 Day 1 (Visit 2) until progression of disease, unacceptable toxicity, death, or discontinuation from the study for any other reason. A treatment cycle consisted of 28 days.

    Drug: Everolimus (RAD001)

Interventions

  • Everolimus (RAD001) 10 mg (two 5mg tablets) given orally once daily and packed in blisters.

    Also known as: RAD001

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) Based on the Assessments by Investigator

    ORR: % of patients whose overall disease response was a complete response (CR) or a partial response (PR) in 8 cycles CR: Complete normalization of all index nodal \& extranodal lesions: Radiological regression to normal size of all lymph nodes \& nodal masses \& complete disappearance of all lesions PR: At least a 50% decrease in the SPD of all index nodal \& extranodal lesions FDG-avid or PET positive prior to therapy: one or more PET positive at previously involved site.At least a 50% increase in the SPD of all index nodal \& extranodal lesions, taking as reference the smallest sum of the product of the diameters of all index lesions recorded at or after baseline . Lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy. Unknown (UNK): Progression not documented \& one or more of the index lesions not assessed or assessed using a different method than baseline at the time of radiologic evaluation. Each cycle was 28 days.

    Time frame: at screening and every threee months beginning at cycle 3 until end of treatment due to progression of disease, unacceptable toxicity, death or discontinuation from the study for any other reason

Secondary outcomes

  1. Time to Overall Response (TTR) Per Kaplan-Meier Estimate

    Time to overall response was defined as the time from the first date of treatment to the date of first documented response of CR or PR. Time to overall response is applied to patients whose best overall response is CR or PR. Patients who drop-out or did not have a response (CR or PR) will be treated as censored at the date of last adequate tumor assessment.

    Time frame: Every three months beginning at Cycle 3 until end of treatment due to progression of disease, unacceptable toxicity, death or discontinuation from the study for any other reason

  2. Duration of Overall Response (DoR)

    The duration of overall response was calculated from the date of first documented response (CR or PR) to the date of first documented disease progression or death due to any cause or start of a new antineoplastic therapy. This only applies to patients whose best overall response is CR or PR.

    Time frame: Every three months beginning at Cycle 3 until end of treatment due to progression of disease, unacceptable toxicity, death or discontinuation from the study for any other reason

  3. Disease Control Rate (DCR)

    The disease control rate was defined as the percentage of patients with a best overall response of CR, PR or stable disease (SD).

    Time frame: Every three months beginning at Cycle 3 until end of treatment due to progression of disease, unacceptable toxicity, death or discontinuation from the study for any other reason

  4. Duration of Disease Control

    The duration of overall response (CR/PR) was applied only to patients whose best overall response was CR or PR. Duration of overall response was calculated from the date of the first documented response of CR or PR to the date of first documented disease progression or death due to any cause or start of a new antineoplastic therapy.

    Time frame: Every three months beginning at Cycle 3 until end of treatment due to progression of disease, unacceptable toxicity, death or discontinuation from the study for any other reason

  5. Progression Free Survival (PFS) by Kaplan-Meier Estimate

    Progression-free survival (PFS) was defined as the time from the first date of treatment to the date of first documented disease progression or death due to any cause or start of a new antineoplastic therapy. An event for PFS was defined as a documented disease progression or death due to any cause or start of a new antineoplastic therapy, whichever occurred first. Cycle = 28 days.

    Time frame: Every three months beginning at Cycle 3 until end of treatment due to progression of disease, unacceptable toxicity, death or discontinuation from the study for any other reason

07

Results

Posted Apr 6, 2016

Participant flow

Participant flow — Overall Study
MilestoneRAD001
Started57
Completed0
Not completed57
Withdrew: Adverse event14
Withdrew: Withdrawal by subject3
Withdrew: Lost to follow-up1
Withdrew: Administrative problems6
Withdrew: Disease progression32
Withdrew: Protocol violation1

Outcome measures

PrimaryOverall Response Rate (ORR) Based on the Assessments by Investigator

ORR: % of patients whose overall disease response was a complete response (CR) or a partial response (PR) in 8 cycles CR: Complete normalization of all index nodal \& extranodal lesions: Radiological regression to normal size of all lymph nodes \& nodal masses \& complete disappearance of all lesions PR: At least a 50% decrease in the SPD of all index nodal \& extranodal lesions FDG-avid or PET positive prior to therapy: one or more PET positive at previously involved site.At least a 50% increase in the SPD of all index nodal \& extranodal lesions, taking as reference the smallest sum of the product of the diameters of all index lesions recorded at or after baseline . Lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy. Unknown (UNK): Progression not documented \& one or more of the index lesions not assessed or assessed using a different method than baseline at the time of radiologic evaluation. Each cycle was 28 days.

Time frame:
at screening and every threee months beginning at cycle 3 until end of treatment due to progression of disease, unacceptable toxicity, death or discontinuation from the study for any other reason
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) Based on the Assessments by Investigator
percentage of participantsRAD001
Complete response (CR)8.8
Partial response (PR)36.8
Response of CR or PR45.6
SecondaryTime to Overall Response (TTR) Per Kaplan-Meier Estimate

Time to overall response was defined as the time from the first date of treatment to the date of first documented response of CR or PR. Time to overall response is applied to patients whose best overall response is CR or PR. Patients who drop-out or did not have a response (CR or PR) will be treated as censored at the date of last adequate tumor assessment.

Time frame:
Every three months beginning at Cycle 3 until end of treatment due to progression of disease, unacceptable toxicity, death or discontinuation from the study for any other reason
Reported as:
Median · Days
Time to Overall Response (TTR) Per Kaplan-Meier Estimate
DaysRAD001
Time to Overall Response (TTR) Per Kaplan-Meier EstimateNA (79.00 to NA)
SecondaryDuration of Overall Response (DoR)

The duration of overall response was calculated from the date of first documented response (CR or PR) to the date of first documented disease progression or death due to any cause or start of a new antineoplastic therapy. This only applies to patients whose best overall response is CR or PR.

Time frame:
Every three months beginning at Cycle 3 until end of treatment due to progression of disease, unacceptable toxicity, death or discontinuation from the study for any other reason
Reported as:
Mean · Days
Duration of Overall Response (DoR)
DaysRAD001
Duration of Overall Response (DoR)350.8 ± 388.63
SecondaryDisease Control Rate (DCR)

The disease control rate was defined as the percentage of patients with a best overall response of CR, PR or stable disease (SD).

Time frame:
Every three months beginning at Cycle 3 until end of treatment due to progression of disease, unacceptable toxicity, death or discontinuation from the study for any other reason
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR)
Percentage of participantsRAD001
Disease Control Rate (DCR)80.7 (68.09 to 89.95)
SecondaryDuration of Disease Control

The duration of overall response (CR/PR) was applied only to patients whose best overall response was CR or PR. Duration of overall response was calculated from the date of the first documented response of CR or PR to the date of first documented disease progression or death due to any cause or start of a new antineoplastic therapy.

Time frame:
Every three months beginning at Cycle 3 until end of treatment due to progression of disease, unacceptable toxicity, death or discontinuation from the study for any other reason
Reported as:
Mean · Days
Duration of Disease Control
DaysRAD001
Duration of Disease Control321.9 ± 394.92
SecondaryProgression Free Survival (PFS) by Kaplan-Meier Estimate

Progression-free survival (PFS) was defined as the time from the first date of treatment to the date of first documented disease progression or death due to any cause or start of a new antineoplastic therapy. An event for PFS was defined as a documented disease progression or death due to any cause or start of a new antineoplastic therapy, whichever occurred first. Cycle = 28 days.

Time frame:
Every three months beginning at Cycle 3 until end of treatment due to progression of disease, unacceptable toxicity, death or discontinuation from the study for any other reason
Reported as:
Median · Days
Progression Free Survival (PFS) by Kaplan-Meier Estimate
DaysRAD001
Progression Free Survival (PFS) by Kaplan-Meier Estimate8.0 (5.07 to 10.96)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RAD001—18/57 (31.6%)56/57 (98.2%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventRAD001
PneumoniaInfections and infestations4/57
PyrexiaGeneral disorders3/57
AnaemiaBlood and lymphatic system disorders2/57
TachycardiaCardiac disorders2/57
Pleural effusionRespiratory, thoracic and mediastinal disorders2/57
HypotensionVascular disorders2/57
ThrombocytopeniaBlood and lymphatic system disorders1/57
Atrial fibrillationCardiac disorders1/57
MyocarditisCardiac disorders1/57
Pericardial effusionCardiac disorders1/57
Most frequent other events
Showing 10 of 80
Most frequent other events
EventRAD001
FatigueGeneral disorders33/57
ThrombocytopeniaBlood and lymphatic system disorders27/57
CoughRespiratory, thoracic and mediastinal disorders27/57
RashSkin and subcutaneous tissue disorders22/57
AnaemiaBlood and lymphatic system disorders18/57
PyrexiaGeneral disorders18/57
DyspnoeaRespiratory, thoracic and mediastinal disorders17/57
DiarrhoeaGastrointestinal disorders15/57
Back painMusculoskeletal and connective tissue disorders15/57
NauseaGastrointestinal disorders14/57

Baseline characteristics

Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)RAD001
Mean36.33 ± 14.101
Sex: Female, Male
Sex: Female, Male(Participants)RAD001
Female33
Male24
08

Study locations

16 sites
  • University of California at Los Angeles UCLS School of Medicine
    Los Angeles, California 90095, United States
  • Rocky Mountain Cancer Centers RMCC - Aurora
    Greenwood Village, Colorado, United States
  • MD Anderson Cancer Center - Orlando
    Orlando, Florida 32806, United States
  • Emory University School of Medicine/Winship Cancer Institute Emory University Med School
    Atlanta, Georgia 30322, United States
  • Lurie Children's Hospital of Chicago Robert H. Lurie Comp Cancer
    Chicago, Illinois 60611, United States
  • Indiana University Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Karmanos Cancer Institute Karmanos-1
    Detroit, Michigan 48201, United States
  • Mayo Clinic - Rochester Mayo Lymphoma Group
    Rochester, Minnesota 55905, United States
  • Washington University School Of Medicine-Siteman Cancer Ctr StudyCoordinator:CLBH589B2201
    St. Louis, Missouri 63110, United States
  • New York Presbyterian Hospital Weill Cornell Med Ctr
    New York, New York 10021, United States
  • Duke University Medical Center Duke University Medical Ctr
    Durham, North Carolina 27710, United States
  • University of Tennessee Cancer Institute Univ Tennessee Cancer
    Memphis, Tennessee 38104, United States
  • University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(3)
    Houston, Texas 77030-4009, United States
  • University of Wisconsin Comprehensive Cancer Center Clinical Science Center - H4
    Madison, Wisconsin 53792, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Publications

  • Johnston PB, Pinter-Brown LC, Warsi G, White K, Ramchandren R. Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma. Exp Hematol Oncol. 2018 May 11;7:12. doi: 10.1186/s40164-018-0103-z. eCollection 2018. PubMed 29774169 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2009, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2009
First posted
Dec 1, 2009
Start
Dec 2009
Primary completionActual
Nov 2014
CompletionActual
Nov 2014
Results first posted
Apr 6, 2016
Last update
May 18, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01022996
Responsible party
Sponsor
First posted
Dec 1, 2009
Start date
Dec 2009
Primary completion
Nov 2014
Completion
Nov 2014
Results posted
Apr 6, 2016
Last update
May 18, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion